Leukemia is a type of hematopoietic stem/progenitor cell malignancy characterized by the
accumulation of immature cells in the blood and bone marrow. Treatment strategies mainly …

The interaction between leukemia cells and the bone microenvironment is known to provide
drug resistance in leukemia cells. This phenomenon, called cell adhesion-mediated drug …

Type I innate lymphoid cells (ILC1s) are critical regulators of inflammation and immunity in
mammalian tissues. However, their function in cancer is mostly undefined. Here, we show …

Simple Summary Chronic myeloid leukemia stem cells (CML LSCs) are a rare and
quiescent population that are resistant to tyrosine kinase inhibitors. CML LSCs have many …

Leukemia is a liquid tumor caused by a hematopoietic stem cell malignant clone, which
seriously affects the normal function of the hematopoietic system. Conventional drugs have …

Acute myeloid leukemia is an aggressive hematopoietic stem cell malignancy with poor
outcomes despite the available treatment options including standard chemotherapy …

Leukemia is an aggressive hematologic neoplastic disease. Therapy-resistant leukemic
stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be …

Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical
course is characterized by progression disease from the early chronic phase (CP) to the fatal …

In chronic myelogenous leukemia (CML), treatment-free remission (TFR) is defined as
maintaining a major molecular response (MMR) without a tyrosine kinase inhibitor (TKI) …

The current scientific literature has extensively explored the potential role of proteasome
inhibitors (PIs) in the NF-κB pathway of leukemia and lymphoma. The ubiquitin-proteasome …